Coronavirus Disease (COVID-19)
Conditions
Brief summary
COVID-19 as a novel disease, different disease patterns were observed worldwide, and many treatment plans were tried. So, it is important to investigate the Egyptian clinical characteristics and different factors that determine the patient's 'outcome
Detailed description
Investigators will convey the Ain Shams University experience as the first university in Egypt to designate one of its hospitals (Ain Shams University Obour Hospital) for management of confirmed COVID19 cases. investigators will try to identify the characteristics of the disease as regards the clinical, laboratory and imaging abnormalities and to assess the outcome determinants. It is a retrospective observational cohort study at Ain Shams University Obour Hospital. All adult patients from both sexes with positive nucleic acid testing for severe adult respiratory syndrome Coronavirus (SARS-CoV-2)will be included. Clinical criteria, laboratory data, radiological findings, hospital course and patient outcome will be anonymously collected from records.
Interventions
DIAGNOSTIC_TESTLab workup (on admission and regularly during follow up).
Complete blood count with differential leucocytic count. Absolute lymphocytic and neutrophilic count. Liver functions: Aspartate transaminase and Alanine transaminase . Renal functions: Blood urea nitrogen, serum Creatinine. HbA1C. C-reactive protein (quantitative). Serum ferritin level. D - dimer level (quantitative). Coagulation profile (Prothrombin time/ Partial thromboplastin time/ International normalized ratio). Troponin level. Arterial blood gases when needed.
Sponsors
Ain Shams University
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult (≥18 years) patients from both sexes with positive nucleic acid testing for severe adult respiratory syndrome Coronavirus (SARS-CoV-2). * Standard of care arm of the ongoing clinical trials will be included in our study.
Exclusion criteria
* mild cases who don't need hospitalization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recovery | Until patient is discharged or up to 12 weeks whichever comes first | Recovery defined as resolution of fever without the use of antipyretics, improvement of respiratory symptoms (e.g., cough, dyspnea) and no need for supplemental oxygen |
| Mortality | Until patient is discharged or up to 12 weeks whichever comes first | All cause mortality |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Functional progression of the COVID 19 disease | Until patient is discharged or up to 12 weeks whichever comes first | increase oxygen demands detected by arterial blood gases analysis and/or pulse oximeter |
| Conversion of nucleic acid testing for SARS-CoV-2 from positive to negative. | Until patient is discharged or up to 12 weeks whichever comes first | Detected by Polymerase Chain Reaction (PCR) test for nasopharyngeal swab |
| Radiological progression of the COVID 19 disease | Until patient is discharged or up to 12 weeks whichever comes first | detected by measuring the extent of pulmonary lesion in high resolution computed tomography (HRCT) of the chest |
Countries
Egypt
Contacts
Primary ContactAshraf Elmaraghy
Outcome results
None listed